Stay updated with breaking news from Athersys Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Athersys (NASDAQ: ATHX) recently received a number of ratings updates from brokerages and research firms: 6/8/2022 – Athersys was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of […]
Webinar scheduled for June 14, 2022 at 5:00 p.m. ETCLEVELAND--(BUSINESS WIRE)--$ATHX #investorconference--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a panel discussion with leading neurology experts...
The Cleveland-based regenerative medicine company is moving the meeting back by about six weeks, to July 28, as it considers implementing a reverse stock split and makes changes to its board of directors.
/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Anti-aging Therapeutics Market (Type of Molecule...
JERSEY CITY, N.J., June 8, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Anti-aging Therapeutics Market (Type of Molecule (Biologics